CEO Ron Bentsur is scheduled to speak at 10:30 a.m. ET in New York; Nuvectis says a webcast will be available in the ...

Opportunities center on targeted complement inhibitors, biologics, small molecules, RNA and gene therapies for rare diseases across ophthalmology, hematology and immunology.Dublin, Sept. 16, 2026 ...

Paroxysmal nocturnal hemoglobinuria has long been one of hematology’s cruelest puzzles: a rare, acquired stem-cell mutation that leaves red blood cells defenseless against the body’s own com ...

By merging bulk and single-cell RNA sequencing with machine learning and lab experiments, researchers have identified smooth ...

Ionis Pharmaceuticals Inc. and partner Roche announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA ...

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

How the Reds set up their catching hierarchy this winter will be closely watched.

SpaceX’s $8B deal sparked selloff in major telecom stocks - but is it warranted? Why Micron Technology deserves its strong ...

Canada's competition watchdog says a healthy market at home is key to strengthening the economy as trade tensions with the ...

As new credit models learn from spending and cash-flow patterns, the challenge is no longer producing an explanation. It is ...

NVCT stock surged on NXP100 PNH deal. Explore catalysts, dilution risk, and pipeline outlook for NXP100/NXP200/NXP900—read the NVCT hold thesis now.

Spread the love“`html Imagine a world where energy is virtually limitless, carbon-free, and incredibly safe. No more burning ...